Genentech, a member of the Roche Group, announced plans to present 16 accepted abstracts spanning both pharmaceutical and diagnostics portfolios at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Congress in Boston, scheduled from November 16 to 19, 2026. The presentation lineup includes two scientific symposia and two oral presentations, focusing on a combined strategy of accurate diagnostic tests and investigational therapeutics.
Among the pipeline updates, Genentech and Roche are initiating the Phase II TARBELA-AD clinical trial, which investigates the oral NLRP3 inhibitor RG6434 for early symptomatic Alzheimer's disease. Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development, noted that while amyloid clearance remains a cornerstone, halting Alzheimer's requires multifaceted strategies, including targeting neuroinflammation through programs like the NLRP3 inhibitor and trontinemab.
In addition to pharmaceuticals, Roche's diagnostics division highlighted its blood-based biomarker portfolio, featuring the Elecsys® pTau217 and Elecsys pTau181 tests. Matt Sause, CEO of Roche Diagnostics, emphasized that the Elecsys pTau217 test is an FDA-cleared, single-biomarker blood test designed to rule in and rule out amyloid pathology, aiming to expand assessment capabilities into primary care and specialist settings.
The pharmaceutical presentations feature several key sessions. On Monday, November 16, a symposium will cover neuroimaging, pharmacokinetics, pharmacodynamics, and safety data from the ongoing Phase Ib/IIa Brainshuttle™ AD study evaluating trontinemab. On Tuesday, November 17, a second symposium will explore neuroinflammation and initial data regarding the NLRP3 inhibitor RG6434, alongside a keynote address by Geoff Kerchner, Global Head of Neurodegeneration Product Development at Roche. An oral presentation scheduled for Wednesday, November 18, will detail the Phase III PrevenTRON study evaluating trontinemab in preclinical Alzheimer's disease.
Furthermore, multiple poster sessions running from Monday, November 16 through Thursday, November 19, will feature clinical, health economic, and real-world data for diagnostic tools like the Elecsys pTau217 and pTau181 tests across various global cohorts and healthcare systems. Genentech and Roche maintain a broad portfolio in Alzheimer's disease research encompassing therapeutics such as trontinemab, nivegacetor, and RG6434, alongside diagnostics including cerebrospinal fluid assays and blood-based tests.
